SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bill small who wrote (186)2/12/1998 2:16:00 PM
From: Steve   of 496
 
Yes I am a holder of GLFD.

I listened to the 1997 year end report conference call and was I kind of taken back by the few analyst presenting questions to the CEO. I think there were a total of 3 questions asked.

Anyway, Dr. Smith (the CEO) sounded optimistic about Gliadel sales for 1998. He said that the RPR marketing people have done a good job in laying the ground work for 1998 sales.

With respect to dopascan, he said they are back on track with respect to phase III trial.

With respect to their lead compound in the neuroimmunoligand program with AMGN, the newer compound is at least 10 times more effective that the GPI 1046 (I think that is the old compound name he said but don't quote me).

Overall, I got a good feeling for the Company--but then again I an not a MD or scientist so I may not have been focusing on the more questionable comments he may have made.

If anybody else listened, I would appreciate their impression.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News